Cancer Therapy: Preclinical Phase I Clinical Pharmacology Study of F14512, a New Polyamine-Vectorized Anticancer Drug, in Naturally Occurring Canine Lymphoma

Abstract

Purpose: F14512 is a new topoisomerase II inhibitor containing a spermine moiety that facilitates selective uptake by tumor cells and increases topoisomerase II poisoning. F14512 is currently in a phase I/II clinical trial in patients with acute myeloid leukemia. The aim of this study was to investigate F14512 potential in a new clinical indication. Because… (More)

Topics

6 Figures and Tables

Cite this paper

@inproceedings{Tierny2015CancerTP, title={Cancer Therapy: Preclinical Phase I Clinical Pharmacology Study of F14512, a New Polyamine-Vectorized Anticancer Drug, in Naturally Occurring Canine Lymphoma}, author={Dominique Tierny and François J Serres and Zacharie Segaoula and Ingrid Bemelmans and E Couffin and ThierryMarchal and Laurent Nguyen and Xavier Thuru and Pierre Ferr and Bruno Gomes}, year={2015} }